Evaluation of the potential of PET-MRI fusion for detection of liver metastases in patients with neuroendocrine tumours

European Radiology

Volumn 22, Issue 2, 2012, Pages 458-467

  Schreiter, Nils F ^a   Nogami, Munenobu ^b   Steffen, Ingo ^a   Pape, Ulrich Frank ^a   Hamm, Bernd ^a   Brenner, Winfried ^a   Röttgen, Rainer ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b KOCHI UNIVERSITY   (Japan)

Author keywords

Ga 68 DOTATOC PET CT; Gd EOB DTPA MRI; Liver metastases; Neuroendocrine tumors; PET MRI

Indexed keywords

GADOXETIC ACID; GALLIUM 68; GALLIUM 68 DOTATOC; RADIOISOTOPE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER SIZE; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; LIVER METASTASIS; MALE; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; TUMOR CLASSIFICATION;

ADULT; AGED; CONTRAST MEDIA; FEMALE; HUMANS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MEDICAL ONCOLOGY; MIDDLE AGED; NEOPLASM METASTASIS; NEUROENDOCRINE TUMORS; OBSERVER VARIATION; OCTREOTIDE; POSITRON-EMISSION TOMOGRAPHY; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SOFTWARE;

EID: 84856593070     PISSN: 09387994     EISSN: 14321084     Source Type: Journal    
DOI: 10.1007/s00330-011-2266-4     Document Type: Article

References (50)

1. T Steinmuller R Kianmanesh M Falconi, et al. 2008 Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endocrine tumors: foregut, midgut, hindgut, and unknown primary Neuroendocrinology 87 47 62 18097131 10.1159/000111037 (Pubitemid 350308294)
2. SK Maithel Y Fong 2009 Hepatic ablation for neuroendocrine tumor metastases J Surg Oncol 100 635 638 20017158 10.1002/jso.21196
3. A Frilling J Li E Malamutmann KW Schmid A Bockisch CE Broelsch 2009 Treatment of liver metastases from neuroendocrine tumours in relation to the extent of hepatic disease Br J Surg 96 175 184 19160361 10.1002/bjs.6468 1:STN:280:DC%2BD1M%2FpvVSlsg%3D%3D
4. T Berge F Linell 1976 Carcinoid tumours. Frequency in a defined population during a 12-year period Acta Pathol Microbiol Scand A 84 322 330 961424 1:STN:280:DyaE283nsVGjsg%3D%3D
5. F Panzuto S Nasoni M Falconi, et al. 2005 Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization Endocr Relat Cancer 12 1083 1092 16322345 10.1677/erc.1.01017 (Pubitemid 41815799)
6. I Madeira B Terris M Voss, et al. 1998 Prognostic factors in patients with endocrine tumours of the duodenopancreatic area Gut 43 422 427 9863490 10.1136/gut.43.3.422 1:STN:280:DyaK1M%2FotVymug%3D%3D (Pubitemid 28414926)
7. P Tomassetti D Campana L Piscitelli, et al. 2005 Endocrine pancreatic tumors: factors correlated with survival Ann Oncol 16 1806 1810 16085691 10.1093/annonc/mdi358 1:STN:280:DC%2BD2MrlvFGmsA%3D%3D (Pubitemid 41631244)
8. JM Sarmiento G Heywood J Rubin DM Ilstrup DM Nagorney FG Que 2003 Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival J Am Coll Surg 197 29 37 12831921 10.1016/S1072-7515(03)00230-8 (Pubitemid 36759176)
9. JM Sarmiento FG Que 2003 Hepatic surgery for metastases from neuroendocrine tumors Surg Oncol Clin N Am 12 231 242 12735141 10.1016/S1055-3207(02)00076-5 (Pubitemid 36210867)
10. D Elias P Lasser M Ducreux, et al. 2003 Liver resection (and associated extrahepatic resections) for metastatic well-differentiated endocrine tumors: a 15-year single center prospective study Surgery 133 375 382 12717354 10.1067/msy.2003.114 (Pubitemid 36515325)
11. RS Chamberlain D Canes KT Brown, et al. 2000 Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg 190 432 445 10757381 10.1016/S1072-7515(00)00222-2 1:STN:280:DC%2BD3c3hvVejtQ%3D%3D (Pubitemid 30181109)
12. H Chen JM Hardacre A Uzar JL Cameron MA Choti 1998 Isolated liver metastases from neuroendocrine tumors: does resection prolong survival? J Am Coll Surg 187 88 92 9660030 10.1016/S1072-7515(98)00099-4 1:STN:280: DyaK1czitFCltQ%3D%3D discussion 92-83 (Pubitemid 28303537)
13. CJ Zech KA Herrmann MF Reiser SO Schoenberg 2007 MR imaging in patients with suspected liver metastases: value of liver-specific contrast agent Gd-EOB-DTPA Magn Reson Med Sci 6 43 52 17510541 10.2463/mrms.6.43
14. TJ Vogl S Kummel R Hammerstingl, et al. 1996 Liver tumors: comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA Radiology 200 59 67 8657946 1:STN:280:DyaK283lslWnsw%3D%3D (Pubitemid 26197732)
15. A Huppertz T Balzer A Blakeborough, et al. 2004 Improved detection of focal liver lesions at MR imaging: multicenter comparison of gadoxetic acid-enhanced MR images with intraoperative findings Radiology 230 266 275 14695400 10.1148/radiol.2301020269 (Pubitemid 37549812)
16. I Buchmann M Henze S Engelbrecht, et al. 2007 Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours Eur J Nucl Med Mol Imaging 34 1617 1626 17520251 10.1007/s00259-007-0450-1 1:STN:280:DC%2BD2srmtlaisQ%3D%3D (Pubitemid 47476920)
17. J Kowalski M Henze J Schuhmacher HR Macke M Hofmann U Haberkorn 2003 Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors Mol Imaging Biol 5 42 48 14499161 10.1016/S1536-1632(03)00038-6 (Pubitemid 36596544)
18. M Gabriel C Decristoforo D Kendler, et al. 2007 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT J Nucl Med 48 508 518 17401086 10.2967/jnumed.106.035667 1:CAS:528:DC%2BD2sXhtVert7jF (Pubitemid 47571404)
19. G Antoch A Bockisch 2009 Combined PET/MRI: a new dimension in whole-body oncology imaging? Eur J Nucl Med Mol Imaging 36 Suppl 1 S113 120 19104802 10.1007/s00259-008-0951-6
20. OF Donati TF Hany CS Reiner, et al. 2010 Value of retrospective fusion of PET and MR images in detection of hepatic metastases: comparison with 18F-FDG PET/CT and Gd-EOB-DTPA-enhanced MRI J Nucl Med 51 692 699 20395324 10.2967/jnumed.109.068510
21. KP Zhernosekov DV Filosofov RP Baum, et al. 2007 Processing of generator-produced 68Ga for medical application J Nucl Med 48 1741 1748 17873136 10.2967/jnumed.107.040378 1:CAS:528:DC%2BD2sXht1GlurnE (Pubitemid 47572722)
22. RC Domingues MP Carneiro FC Lopes RC Domingues LM da Fonseca EL Gasparetto 2009 Whole-body MRI and FDG PET fused images for evaluation of patients with cancer AJR Am J Roentgenol 192 1012 1020 19304708 10.2214/AJR.08.1498
23. SK Kim HJ Choi SY Park, et al. 2009 Additional value of MR/PET fusion compared with PET/CT in the detection of lymph node metastases in cervical cancer patients Eur J Cancer 45 2103 2109 19403303 10.1016/j.ejca.2009.04.006
24. ER DeLong DM DeLong DL Clarke-Pearson 1988 Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach Biometrics 44 837 845 3203132 10.2307/2531595 1:STN:280: DyaL1M%2Fns12ksQ%3D%3D
25. J Ward PJ Robinson JA Guthrie, et al. 2005 Liver metastases in candidates for hepatic resection: comparison of helical CT and gadolinium- and SPIO-enhanced MR imaging Radiology 237 170 180 16126930 10.1148/radiol. 2371041444 (Pubitemid 41346161)
26. MC Niekel S Bipat J Stoker 2010 Diagnostic imaging of colorectal liver metastases with CT, MR imaging, FDG PET, and/or FDG PET/CT: a meta-analysis of prospective studies including patients who have not previously undergone treatment Radiology 257 674 684 20829538 10.1148/radiol.10100729
27. G Kong C Jackson DM Koh, et al. 2008 The use of 18F-FDG PET/CT in colorectal liver metastases-comparison with CT and liver MRI Eur J Nucl Med Mol Imaging 35 1323 1329 18347794 10.1007/s00259-008-0743-z 1:STN:280: DC%2BD1cznvFOqsg%3D%3D
28. MP Debray O Geoffroy JP Laissy, et al. 2001 Imaging appearances of metastases from neuroendocrine tumours of the pancreas Br J Radiol 74 1065 1070 11709476 1:STN:280:DC%2BD3MnmtlKhsw%3D%3D (Pubitemid 33121143)
29. EK Paulson VG McDermott MT Keogan DM DeLong MG Frederick RC Nelson 1998 Carcinoid metastases to the liver: role of triple-phase helical CT Radiology 206 143 150 9423664 1:STN:280:DyaK1c%2FosFOhsA%3D%3D (Pubitemid 28062998)
30. S Namasivayam DR Martin S Saini 2007 Imaging of liver metastases: MRI Cancer Imaging 7 2 9 17293303 10.1102/1470-7330.2007.0002 (Pubitemid 47528076)
31. TR Bader RC Semelka VC Chiu DM Armao JT Woosley 2001 MRI of carcinoid tumors: spectrum of appearances in the gastrointestinal tract and liver J Magn Reson Imaging 14 261 269 11536403 10.1002/jmri.1182 1:STN:280: DC%2BD3MvptFygsQ%3D%3D (Pubitemid 32801060)
32. DA Bluemke D Sahani M Amendola, et al. 2005 Efficacy and safety of MR imaging with liver-specific contrast agent: U.S. multicenter phase III study Radiology 237 89 98 16126918 10.1148/radiol.2371031842 (Pubitemid 41346150)
33. J Halavaara J Breuer C Ayuso, et al. 2006 Liver tumor characterization: comparison between liver-specific gadoxetic acid disodium-enhanced MRI and biphasic CT-a multicenter trial J Comput Assist Tomogr 30 345 354 16778605 10.1097/00004728-200605000-00001 (Pubitemid 43922248)
34. PG Kele EJ van der Jagt 2010 Diffusion weighted imaging in the liver World J Gastroenterol 16 1567 1576 20355235 10.3748/wjg.v16.i13.1567
35. Holzapfel K, Eiber MJ, Fingerle AA, Bruegel M, Rummeny EJ, Gaa J (2011) Detection, classification, and characterization of focal liver lesions: Value of diffusion-weighted MR imaging, gadoxetic acid-enhanced MR imaging and the combination of both methods Abdom Imaging. 2011 May 20. [Epub ahead of print]PMID: 21597893
36. Kenis C, Deckers F, De Foer B, Van Mieghem F, Van Laere S, Pouillon M (2011) Diagnosis of liver metastases: Can diffusion-weighted imaging (DWI) be used as a stand alone sequence? Eur J Radiol. 2011 Mar 3. [Epub ahead of print] PMID: 21377305
37. J Ruf F Heuck J Schiefer, et al. 2010 Impact of Multiphase 68Ga-DOTATOC-PET/CT on therapy management in patients with neuroendocrine tumors Neuroendocrinology 91 101 109 19996582 10.1159/000265561 1:CAS:528: DC%2BC3cXotVWrtw%3D%3D
38. A Frilling GC Sotiropoulos A Radtke, et al. 2010 The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors Ann Surg 252 850 856 21037441 10.1097/SLA.0b013e3181fd37e8
39. O Schillaci A Spanu F Scopinaro, et al. 2003 Somatostatin receptor scintigraphy in liver metastasis detection from gastroenteropancreatic neuroendocrine tumors J Nucl Med 44 359 368 12621001 1:CAS:528: DC%2BD3sXislKntbo%3D (Pubitemid 39586011)
40. RP Baum 2009 Molecular imaging of neuroendocrine tumors using 68Ga-labeled peptides (Somatostatin Receptor PET/CT) Nuklearmediziner 32 115 130 10.1055/s-0029-1215599
41. M Cimitan A Buonadonna R Cannizzaro, et al. 2003 Somatostatin receptor scintigraphy versus chromogranin A assay in the management of patients with neuroendocrine tumors of different types: clinical role Ann Oncol 14 1135 1141 12853358 10.1093/annonc/mdg279 1:STN:280:DC%2BD3szitlCqsQ%3D%3D (Pubitemid 36950180)
42. M Rodrigues M Gabriel D Heute D Putzer A Griesmacher I Virgolini 2008 Concordance between results of somatostatin receptor scintigraphy with 111In-DOTA-DPhe 1-Tyr 3-octreotide and chromogranin A assay in patients with neuroendocrine tumours Eur J Nucl Med Mol Imaging 35 1796 1802 18425512 10.1007/s00259-008-0794-1 1:CAS:528:DC%2BD1cXhtFCjtbzF
43. K Mussig MO Oksuz K Dudziak, et al. 2010 Association of somatostatin receptor 2 immunohistochemical expression with [111In]-DTPA octreotide scintigraphy and [68Ga]-DOTATOC PET/CT in neuroendocrine tumors Horm Metab Res 42 599 606 20422506 10.1055/s-0030-1253354 1:STN:280:DC%2BC3cnkt1SksQ%3D%3D
44. DJ Kwekkeboom EP Krenning K Scheidhauer, et al. 2009 ENETS consensus guidelines for the standards of care in neuroendocrine tumors: somatostatin receptor imaging with (111)In-pentetreotide Neuroendocrinology 90 184 189 19713709 10.1159/000225946 1:CAS:528:DC%2BD1MXhtVGgs7vO
45. MD Seemann 2005 Whole-body PET/MRI: the future in oncological imaging Technol Cancer Res Treat 4 577 582 16173829 (Pubitemid 41446811)
46. RJ Hicks EW Lau 2009 PET/MRI: a different spin from under the rim Eur J Nucl Med Mol Imaging 36 Suppl 1 S10 14 19104800 10.1007/s00259-008-0966-z
47. AG Rockall RH Reznek 2007 Imaging of neuroendocrine tumours (CT/MR/US) Best Pract Res Clin Endocrinol Metab 21 43 68 17382265 10.1016/j.beem.2007.01. 003 1:CAS:528:DC%2BD2sXjsVSqt7o%3D (Pubitemid 46436731)
48. AJ Lemke SM Niehues N Hosten, et al. 2004 Retrospective digital image fusion of multidetector CT and 18F-FDG PET: clinical value in pancreatic lesions-a prospective study with 104 patients J Nucl Med 45 1279 1286 15299049 (Pubitemid 47618523)
49. H Amthauer J Ruf M Bohmig, et al. 2004 Diagnosis of neuroendocrine tumours by retrospective image fusion: is there a benefit? Eur J Nucl Med Mol Imaging 31 342 348 14652697 10.1007/s00259-003-1379-7 1:STN:280: DC%2BD2c7gtVCjtA%3D%3D (Pubitemid 38314077)
50. V Prasad V Ambrosini M Hommann D Hoersch S Fanti RP Baum 2010 Detection of unknown primary neuroendocrine tumours (CUP-NET) using (68)Ga-DOTA-NOC receptor PET/CT Eur J Nucl Med Mol Imaging 37 67 77 19618183 10.1007/s00259-009-1205-y 1:CAS:528:DC%2BD1MXhsFCktLrF